Spectrum Pharmaceuticals (NASDAQ:SPPI) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 25 percent increase over losses of $(0.16) per share from the same period last year.
Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $355
Barclays analyst Geoff Meacham maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $333 to $355.
